Shire Expands Product Lines
UK age-related disease specialist Shire Pharmaceuticals has entered into two further agreements to expand its range of prescription products. The agreements are with Norway's Hafslund Nycomed and Istituto Gentili of Italy.
Hafslund Nycomed has provided additional marketing rights for its range of calcium products. Under the new arrangements, Shire gains additional territorial rights covering South Africa and certain Middle East and Asian markets and an extension of its rights in the UK and Republic of Ireland for a further 10 years, renewable after that time.
Since 1988, Shire has marketed an increasing number of Nycomed's products and the two companies are cooperating on new product developments and copromotional activities in the UK. The company has become the leading player in the calcium prescription market in the UK, with nearly 40% of the cash market share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze